文献速递甲状腺疾病

超声模式与临床参数能否辅助分子检测预测甲状腺癌风险

Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology?
PubMed 文献 · Thyroid · 2021-09-01

该多中心研究纳入257个细胞学不确定的甲状腺结节,评估超声模式与临床参数能否在ThyroSeq v3分子检测基础上进一步预测甲状腺癌或NIFTP风险。结果显示ATA与TI-RADS超声分类均未显著提升TSv3的预测能力,仅男性性别可能贡献额外风险信息。

要点

  • ATA与TI-RADS超声分类未在TSv3基础上显著提升癌症/NIFTP预测。
  • TSv3阳性与癌症/NIFTP强相关(OR 61.39,p<0.0001)。
  • 仅男性性别可能为TSv3之外潜在贡献风险的临床参数(p=0.095)。

核心结论

  • 在细胞学不确定且行分子检测的甲状腺结节中,ATA与TI-RADS超声评分系统均未能在TSv3预测基础上进一步提供癌症/NIFTP风险信息。
  • 年龄与Bethesda分类在单变量分析中与癌症/NIFTP概率相关,但在序贯列线图中相对TSv3的高预测能力增量价值有限。
  • 患者性别可能对细胞学不确定甲状腺结节的癌症/NIFTP风险有贡献。

研究设计与样本

  • 多中心研究,纳入来自10个研究中心的232例患者共257个细胞学不确定且ThyroSeq v3检测结果可解读的甲状腺结节。
  • 采用单变量和多变量逻辑回归分析数据。

主要发现

  • 癌症/NIFTP的存在与TSv3阳性结果相关(比值比61.39,p<0.0001)。
  • 单变量回归中,患者性别、年龄和Bethesda分类与癌症/NIFTP概率相关(各项p<0.05)。
  • ATA(p=0.1211)与TI-RADS(p=0.1359)超声分类呈阳性趋势但均未达统计学显著。
  • 包含性别、年龄、Bethesda分类和ATA超声模式的模型(模型1)C指数为0.653,R2=0.108;加入TSv3后C指数升至0.888,R2=0.572。
  • 在模型1加入TSv3后,年龄(p=0.341)、Bethesda分类(p=0.272)和ATA超声模式(p=0.264)均不显著,除TSv3(p<0.0001)外仅男性性别可能贡献风险(p=0.095)。

临床怎么用

  • 对于细胞学不确定的甲状腺结节,分子检测TSv3是癌症/NIFTP风险的主要预测工具。
  • ATA或TI-RADS超声分类不宜在TSv3结果之上额外用于调整癌症/NIFTP风险预测。
  • 患者性别(男性)可能作为TSv3之外的辅助风险参考因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Molecular testing (MT) is commonly used to refine cancer probability in thyroid nodules with indeterminate cytology. Whether or not ultrasound (US) patterns and clinical parameters can further inform the risk of thyroid cancer in nodules predicted to be positive or negative by MT remains unknown. The aim of this study was to test if clinical parameters, including patient age, sex, nodule size (by US), Bethesda category (III, IV, V), US pattern (American Thyroid Association [ATA] vs. American College of Radiology Thyroid Image Reporting and Data System [TI-RADS] systems), radiation exposure, or family history of thyroid cancer can modify the probability of thyroid cancer or noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) predicted by MT. Methods: We studied 257 thyroid nodules in 232 patients from 10 study centers with indeterminate fine needle aspiration cytology and informative MT results using the ThyroSeq v3 genomic classifier (TSv3). Univariate and multivariate logistic regression was used for data analysis. Results: The presence of cancer/NIFTP was associated with positive TSv3 results (odds ratio 61.39, p < 0.0001). On univariate regression, patient sex, age, and Bethesda category were associated with cancer/NIFTP probability (p < 0.05 for each). Although ATA (p = 0.1211) and TI-RADS (p = 0.1359) US categories demonstrated positive trends, neither was significantly associated with cancer/NIFTP probability. A multivariate regression model incorporating the four most informative non-MT covariates (sex, age, Bethesda category, and ATA US pattern; Model No. 1) yielded a C index of 0.653; R2 = 0.108. When TSv3 was added to Model number 1, the C index increased to 0.888; R2 = 0.572. However, age (p = 0.341), Bethesda category (p = 0.272), and ATA US pattern (p = 0.264) were nonsignificant, and other than TSv3 (p < 0.0001), male sex was the only non-MT parameter that potentially contributed to cancer/NIFTP risk (p = 0.095). The simplest and most efficient clinical model (No. 3) incorporated TSv3 and sex (C index = 0.889; R2 = 0.588). Conclusions: In this multicenter study of thyroid nodules with indeterminate cytology and MT, neither the ATA nor TI-RADS US scoring systems further informed the risk of cancer/NIFTP beyond that predicted by TSv3. Although age and Bethesda category were associated with cancer/NIFTP probability on univariate analysis, in sequential nomograms they provided limited incremental value above the high predictive ability of TSv3. Patient sex may contribute to cancer/NIFTP risk in thyroid nodules with indeterminate cytology.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Figge JJ, Gooding WE, Steward DL, et al. Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology? Thyroid. 2021. PMID: 34340592. doi:10.1089/thy.2021.0119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。